(Reuters) -India’s Cipla reported on Thursday second-quarter profit that beat market expectations, helped by sustained demand for its respiratory drugs.

India’s third-largest drugmaker by sales reported a 3.7% rise in consolidated net profit to 13.51 billion rupees ($153.7 million) in the quarter ended September 30, beating analysts’ estimates of 13.47 billion rupees billion rupees, per data compiled by LSEG.

($1 = 87.8950 Indian rupees)

(Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala)

See Full Page